Ateganosine

Potential breakthrough therapeutic targets $50B+ global immunotherapy market 潜在的突破性治疗靶点，价值500亿美元以上的全球免疫治疗市场1 1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- 芝加哥，2026年3月31日（环球新闻社）--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a poster presented on March 27, 2026, at the European Lung Cancer Congress 2026 (ELCC), a premier thoracic oncology forum held March 25-28, 2026, in Copenhagen, Denmark.. MAIA生物技术公司（纽约证券交易所代码：MAIA）（“MAIA”，“公司”），一家专注于开发癌症靶向免疫疗法的临床阶段生物制药公司，于2026年3月27日在2026年欧洲肺癌大会（ELCC）上公布了海报展示的亮点。该会议是顶级胸部肿瘤论坛，于2026年3月25日至28日在丹麦哥本哈根举行。MAIA reports overall survival (OS) beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of its ongoing Phase 2 THIO-101 clinical trial in non-small cell lung cancer (NSCLC). The patients did not receive subsequent lines of therapy. MAIA 报告了其正在进行的 2 期 THIO-101 临床试验中，针对非小细胞肺癌（NSCLC）在 A 部分和 B 部分接受 ateganosine 与 cemiplimab 序贯治疗的八名患者的两年以上总生存期（OS）。这些患者未接受后续治疗。The eight patients featured in the poster include: 海报中的八位患者包括：“It’s very encouraging to see such outstanding survival from these patients extending beyond our 24-month trial protocol and without any subsequent treatment. OS surpassing two-years bodes well as we continue to monitor patients in our ongoing Phase 3 pivotal trial and in THIO-101 Part C,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “看到这些患者在我们24个月的试验方案之外仍然有如此出色的生存期，并且没有接受任何后续治疗，这非常令人鼓舞。总生存期超过两年是一个好兆头，因为我们继续监测正在进行的三期关键试验以及THIO-101 C部分中的患者。”MAIA创始人兼首席执行官弗拉德·维托克医学博士表示。“These results illuminate ateganosine’s valuable role in targeting telomeres to eliminate NSCLC tumor cells and support this treatment—ateganosine sequenced by a CPI—as a potential breakthrough therapeutic option for NSCLC.”. “这些结果阐明了ateganosine在靶向端粒以消除NSCLC肿瘤细胞方面的宝贵作用，并支持这种治疗——ateganosine与CPI序贯使用——作为NSCLC潜在的突破性治疗选择。”THIO-101 treated 79 patients in Parts A and B of the trial. The Part C expansion is currently enrolling up to 48 participants in Asia and Europe. Treatment with ateganosine followed by cemiplimab (Libtayo THIO-101 在试验的 A 部分和 B 部分治疗了 79 名患者。C 部分扩展目前正在亚洲和欧洲招募多达 48 名参与者。治疗采用阿特加诺星后继以西米普利单抗（Libtayo）。® ®) has shown an acceptable safety profile to date in a heavily pre-treated population. ）在经过大量预处理的人群中，迄今为止已显示出可接受的安全性。MAIA’s ELCC poster is available on MAIA’s website at MAIA的ELCC海报可以在MAIA的网站上找到，地址是maiabiotech.com/publications maiabiotech.com/publications. 。About Ateganosine 关于AteganosineAteganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. Ateganosine（THIO、6-thio-dG 或 6-thio-2'-脱氧鸟苷）是一种首创的端粒靶向研究药物，目前正处于临床开发阶段，以评估其在非小细胞肺癌（NSCLC）中的活性。端粒以及端粒酶在癌细胞的存活及其对现有疗法的耐药性方面发挥着关键作用。The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. 修饰核苷6-硫代-2'-脱氧鸟苷诱导端粒酶依赖性端粒DNA修饰、DNA损伤反应和选择性癌细胞死亡。Ateganosine损伤的端粒片段在胞质微核中积累，并激活先天性（cGAS/STING）和适应性（T细胞）免疫反应。The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.. 阿特加诺星序贯PD-(L)1抑制剂治疗在晚期体内癌症模型中，通过诱导癌症类型特异性免疫记忆，产生了深刻且持久的肿瘤消退。阿特加诺星目前正被开发用于非小细胞肺癌（NSCLC）患者的二线或更后线治疗，这些患者已经超出标准治疗方案中现有检查点抑制剂的疗效范围。About THIO-101 Phase 2 Clinical Trial 关于THIO-101二期临床试验 THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo THIO-101是一项多中心、开放标签、剂量探索的II期临床试验。这是首个旨在评估在PD-(L)1抑制剂治疗后使用阿特加诺星抗肿瘤活性的试验。该试验正在测试在使用西米普利单抗（Libtayo）之前给予低剂量阿特加诺星的假设。® ®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. ）将增强并延长先前无反应或产生耐药性并在含另一种检查点抑制剂的一线治疗方案后进展的晚期非小细胞肺癌患者的免疫反应。试验设计有两个主要目标：（1）评估作为抗癌化合物和免疫激活引物的ateganosine的安全性和耐受性；（2）使用总体反应率（ORR）作为主要临床终点来评估ateganosine的临床疗效。The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo. 研究的扩展将评估接受三线治疗、对先前的检查点抑制剂治疗和化疗产生耐药性的晚期非小细胞肺癌患者的总体反应率。治疗方案为先使用ateganosine，随后使用cemiplimab（Libtayo）。® ®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944. ）在经过大量预处理的人群中，到目前为止显示出可接受的安全性。有关此二期试验的更多信息，请使用标识符 NCT05208944 访问 ClinicalTrials.gov。About MAIA Biotechnology, Inc. 关于MAIA生物技术公司MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. MAIA 是一家专注于靶向治疗和免疫肿瘤学的公司，致力于开发和商业化具有新颖作用机制的潜在首创药物，旨在有意义地改善和延长癌症患者的生命。我们的主要项目是 ateganosine（THIO），这是一种潜在的首创癌症端粒靶向剂，目前正处于临床开发阶段，用于治疗端粒酶阳性的非小细胞肺癌（NSCLC）患者。For more information, please visit . 如需更多信息，请访问 。www.maiabiotech.com www.maiabiotech.com. 。Forward Looking Statements 前瞻性声明MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. MAIA提醒您，本新闻稿中除历史事实陈述之外的所有陈述均为前瞻性陈述。前瞻性陈述受到已知和未知风险、不确定性以及其他可能导致我们或我们行业的实际结果、活动水平、表现或成就与这些陈述所预期的情况有重大差异的因素的影响。The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. 使用诸如“可能”、“也许”、“将”、“应该”、“可以”、“预期”、“计划”、“预期”、“相信”、“估计”、“预测”、“打算”、“未来”、“潜在”或“继续”等词语以及其他类似表达，旨在识别前瞻性陈述。然而，缺少这些词语并不意味着陈述不是前瞻性的。For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. 例如，我们关于以下方面的所有陈述：(i) 我们临床前和临床研究以及我们的研发计划的启动、时间、成本、进展和结果，(ii) 我们将产品候选者推进到临床研究并成功完成这些研究的能力，(iii) 监管文件提交和批准的时间或可能性，(iv) 我们开发、制造和商业化我们的产品候选者并改进制造工艺的能力，(v) 我们产品候选者的市场接受速度和程度，(vi) 我们产品候选者市场的规模和增长潜力以及我们服务这些市场的能力，以及 (vii) 我们对我们获得并维持产品候选者知识产权保护能力的预期，均为前瞻性陈述。All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expr. 所有前瞻性声明均基于我们管理层的当前估计、假设和预期，尽管我们认为这些是合理的，但本质上存在不确定性。任何前瞻性声明表达。Investor Relations Contact 投资者关系联系人+1 (872) 270-3518 +1 (872) 270-3518ir@maiabiotech.com ir@maiabiotech.com1 1Immune Checkpoint Inhibitors Market Analysis by Mordor Intelligence, July 2025 Mordor Intelligence 免疫检查点抑制剂市场分析，2025年7月 2 2Girard N, et al. J Thorac Onc 2009;12:1544-1549 吉拉德 N 等。《胸腔肿瘤学杂志》2009年；12月：1544-1549页3 3https://clinicaltrials.gov/study/NCT01168973?tab=results https://clinicaltrials.gov/study/NCT01168973?tab=resultsReleased March 31, 2026 发布于2026年3月31日

Potential breakthrough therapeutic targets $50B+ global immunotherapy market 1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a poster presented on March 27, 2026, at the European Lung Cancer Congress 2026 (ELCC), a premier thoracic oncology forum held March 25-28, 2026, in Copenhagen, Denmark. MAIA reports overall survival (OS) beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of its ongoing Phase 2 THIO-101 clinical trial in non-small cell lung cancer (NSCLC). The patients did not receive subsequent lines of therapy. The eight patients featured in the poster include: 1 patient in third-line (3L) therapy with survival of 33 months. Expected survival in this heavily pre-treated population is 5.8 months. 2 4 patients in 2L therapy with survival over 30 months. Documented OS for standard of care treatment (chemotherapy or checkpoint inhibitors alone) in second-line (2L) therapy is 10.5 months. 3 All patients have failed previous treatment (prior to THIO-101) with a checkpoint inhibitor (CPI) alone. All patients completed 29-34 cycles of therapy, except for 1 patient who completed 2 cycles of therapy with survival follow-up of 725 off therapy. 5 of the 8 patients have survival follow-up ongoing. “It’s very encouraging to see such outstanding survival from these patients extending beyond our 24-month trial protocol and without any subsequent treatment. OS surpassing two-years bodes well as we continue to monitor patients in our ongoing Phase 3 pivotal trial and in THIO-101 Part C,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “These results illuminate ateganosine’s valuable role in targeting telomeres to eliminate NSCLC tumor cells and support this treatment—ateganosine sequenced by a CPI—as a potential breakthrough therapeutic option for NSCLC.” THIO-101 treated 79 patients in Parts A and B of the trial. The Part C expansion is currently enrolling up to 48 participants in Asia and Europe. Treatment with ateganosine followed by cemiplimab (Libtayo ® ) has shown an acceptable safety pro date in a heavily pre-treated population. MAIA’s ELCC poster is available on MAIA’s website at maiabiotech.com/publications . About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About THIO-101 Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo ® ) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo ® ) has shown an acceptable safety pro date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit . Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries. Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com 1 Immune Checkpoint Inhibitors Market Analysis by Mordor Intelligence, July 2025 2 Girard N, et al. J Thorac Onc 2009;12:1544-1549 3